Review Article

Published in:
Volume 6 / Year 2017 / Issue 4

Major lessons learned from Zarxio’s US launch: the start of a biosimilar revolution

Page: 165-73

Introduction: Launched in 2015, Zarxio™ (filgrastim-sndz) was the first biosimilar to gain US Food and Drug Administration (FDA) approval. In contrast, the first biosimilar was launched in Europe in 2006.… Read More »

Go Back Print